Loading clinical trials...
Loading clinical trials...
A French, Prospective, Observational, Multicenter Study of Patients Treated With Nivolumab Plus Chemotherapy as First Line Treatment in Advanced or Metastatic Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma or Gastric Adenocarcinoma [METAGIO]
Conditions
Interventions
nivolumab + chemotherapy
Locations
2
France
Local Institution - 0001
Paris, France
Kappa Santé
Paris, France
Start Date
December 10, 2024
Primary Completion Date
August 31, 2028
Completion Date
August 31, 2028
Last Updated
April 3, 2026
NCT06340711
NCT06901531
NCT05677490
NCT07282912
NCT07001748
NCT05753306
Lead Sponsor
Bristol-Myers Squibb
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions